scholarly journals Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia: systematic review of randomized controlled trials

2013 ◽  
Vol 15 (4) ◽  
pp. 471-482 ◽  
Author(s):  
Chun Ho Ma ◽  
Wai Ling Lin ◽  
Sing Leung Lui ◽  
Xun-Yuan Cai ◽  
Vivian Taam Wong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Benign Prostatic Hyperplasia ◽  
Herbal Medicine ◽  
Randomized Controlled Trials ◽  
Chinese Herbal Medicine ◽  
Prostatic Hyperplasia ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Randomized Controlled ◽  
Chinese Herbal

scholarly journals Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review of Randomized Controlled Trials

2014 ◽  
Vol 2014 ◽  
pp. 1-16
Author(s):  
Ai-ju Liu ◽  
Hui-qin Li ◽  
Ji-huang Li ◽  
Yuan-yuan Wang ◽  
Dong Chen ◽  
...  
Keyword(s):  
Systematic Review ◽  
Herbal Medicine ◽  
Randomized Controlled Trials ◽  
Chinese Herbal Medicine ◽  
Aspirin Resistance ◽  
Current Evidence ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Randomized Controlled ◽  
Chinese Herbal

Aspirin resistance (AR) is a prevalent phenomenon and leads to significant clinical consequences, but the current evidence for effective interventional strategy is insufficient. The objective of this systematic review is thus to assess the efficacy and safety of Chinese herbal medicine (CHM) for AR. A systematical literature search was conducted in 6 databases until December 2012 to identify randomized controlled trials (RCTs) of CHM for AR. As a result, sixteen RCTs with a total of 1011 subjects were identified, suggesting that the interests of the medical profession and the public in the use of CHM for AR have grown considerably in the recent years. Tongxinluo capsule and Danshen-based prescriptions were the most frequently used herbal prescriptions, while danshen root, milkvetch root, Leech, and Rosewood were the most frequently used single herbs. Despite the apparent reported positive findings, it is premature to determine the efficacy and safety of CHM for the treatment of AR due to poor methodological quality and insufficient safety data. However, CHMs appeared to be well tolerated in all included studies. Thus, CHM as a promising candidate is worthy of improvement and development for further clinical AR trials. Large sample-size and well-designed rigorous RCTs are needed.

Sign in / Sign up

Export Citation Format

Share Document